4-Phenylbutyric Acid
4-PHENYLBUTANOIC ACID · PHENYLBUTYRIC ACID · Benzenebutanoic acid · Buphenyl · Benzenebutyric acid · PHENYLBUTYRIC-4 ACID · NSC 295 · 4-benzene acid
식별자 및 물리적 특성
| CAS No. | 1821-12-1 |
|---|---|
| 분자식 | C10H12O2 |
| 평균 분자량 | 164.2 g/mol |
| 단동위원소 질량 | 164.08372962 g/mol |
| SMILES | O=C(O)CCCc1ccccc1 |
| InChIKey | OBKXEAXTFZPCHS-UHFFFAOYSA-N |
| PubChem CID | 4775 |
| ChEMBL | CHEMBL1469 |
| ChEBI | CHEBI:41500 |
| EC No. | 217-341-8 |
| DTXSID | DTXSID2037631 |
화학 및 물리적 성질
| XLogP | 2.4 |
|---|---|
| 극성 표면적 | 37.3 |
| 수소 결합 공여자 수 | 1 |
| 수소 결합 수용자 수 | 2 |
| 회전 가능 결합 수 | 4 |
| 무거운 원자 수 | 12 |
| 형식 전하 | 0 |
| 복잡도 | 137 |
| 물질 분류 | Other Classes -> Organic AcidsIndustrial compound |
| 의약품 | Pharmaceuticals -> Listed in ZINC15 |
| LogP(분배 계수) | 2.422.32 |
| 용해도 | 18 mg/mL5.3g/L |
| 끓는 점 | 290.00 °C. @ 760.00 mm Hg165 °C10 mm Hg(lit.) |
| 녹는점 | 47 - 49 °C49-51 °C(lit.) |
| 증기압 | 0.000664 [mmHg] |
| Physical Description | White or off-white powder[Alfa Aesar MSDS]Solid |
| 밀도 | 1.0326 (rough estimate) |
| 굴절률 | 1.5405 (estimate) |
| 인화점 | >230 °F |
| 저장 조건 | Sealed in dry,Room Temperature |
| 물리적 상태 | 결정성 분말 |
| pKa(산도 계수) | 4.76(at 25℃) |
| 색상 | 흰색에서 약간 노란색 |
| 용해도 | 40°C에서 5.3g/L |
| BRN | 638180 |
| InChI | 1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12) |
| InChIKey | OBKXEAXTFZPCHS-UHFFFAOYSA-N |
| SMILES | OC(=O)CCCc1ccccc1 |
| LogP(분배 계수) | 2.420 |
| NIST | 4-Phenylbutanoic acid(1821-12-1) |
| EPA | 4-Phenylbutyric acid (1821-12-1) |
화학적 성질
4-Phenylbutyric acid is white to slightly yellowish crystalline powder. It is slightly soluble in chloroform and methanol. Its solubility in water is 5.3 g/l (at 40 °C).
안전 및 규제
| GHS 분류 | WarningH315 (83.3%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 12 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 규제 정보 | Status: Active Update: 15-05-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/16079Benzenebutanoic acid: Does not have an individual approval but may be used under an appropriate group standard |
| 유해성 요약 | A skin and strong eye irritant[Alfa Aesar MSDS] See Butyric acid. |
| Hazard Classes and Categories | Skin Irrit. 2 (83.3%) |
| Hepatotoxicity | While the urea cycle disorders are caused by deficiencies of hepatic enzymes responsible for the elimination of nitrogen, patients generally present with hyperammonemia without other features or biochemical evidence of hepatic injury. Thus, serum aminotransferase, alkaline phosphatase and bilirubin levels are generally normal or only mildly elevated. Newborns presenting with hyperammonemia may have hepatomegaly but other, non-urea cycle, liver function is normal as is hepatic histology. Phenylbutyrate can help to lower ammonia levels acutely and manage to keep them in the normal or near normal range, but generally does not affect other liver functions. In open label studies, a small proportion of patients (particularly with ornithine transcarbamylase [OTC] deficiency) have had ALT or AST elevations, but these have generally been attributed to the underlying condition or its complications. Phenylbutyrate has not been linked to instances of clinically apparent liver injury with jaundice. |
| 수질 위해 등급(WGK) | 3 |
| TSCA 등재 상태 | TSCA listed |
| 관세 코드 | 29163900 |
| 위험 문구(R) | 36/37/38 |
| 위험 표시 | Xi |
| 안전 문구(S) | 22-24/25-36-26 |
| 위험 참고 사항 | Irritant |
| 저장 분류 | 11 - Combustible Solids |
용도
일반 설명
4-Phenylbutyric acid (4-PBA) is a small-molecular-weight fatty acid with a terminal aromatic group, and its sodium salt (sodium 4-phenyl butyrate) has been used for the treatment of urea cycle disorders. This molecule is also used for the treatment of sickle cell diseases and thalassemia owing to its ability to activate β-globin transcription. Moreover, 4-PBA is employed as an orally bioavailable agent for the treatment of spinal muscular atrophy (SMA) and tumors. Neuroprotective Effects of 4-phenylbutyric Acid and Its Derivatives: Possible Therapeutics for Neurodegenerative Diseases
제조 및 합성 방법
제조 방법
4-phenylbutyric acid is obtained by the reaction of benzene with butyrolactone in the presence of aluminum chloride, followed by neutralization with base.Synthesis of 4-phenylbutyric acid